nach oben

Erschienen in:

Open Access 01.09.2011 | Article

Role for inducible cAMP early repressor in promoting pancreatic beta cell dysfunction evoked by oxidative stress in human and rat islets

verfasst von: D. Favre, G. Niederhauser, D. Fahmi, V. Plaisance, S. Brajkovic, N. Beeler, F. Allagnat, J. A. Haefliger, R. Regazzi, G. Waeber, A. Abderrahmani

Erschienen in: Diabetologia | Ausgabe 9/2011

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Pro-atherogenic and pro-oxidant, oxidised LDL trigger adverse effects on pancreatic beta cells, possibly contributing to diabetes progression. Because oxidised LDL diminish the expression of genes regulated by the inducible cAMP early repressor (ICER), we investigated the involvement of this transcription factor and of oxidative stress in beta cell failure elicited by oxidised LDL.

Methods

Isolated human and rat islets, and insulin-secreting cells were cultured with human native or oxidised LDL or with hydrogen peroxide. The expression of genes was determined by quantitative real-time PCR and western blotting. Insulin secretion was monitored by EIA kit. Cell apoptosis was determined by scoring cells displaying pycnotic nuclei.

Results

Exposure of beta cell lines and islets to oxidised LDL, but not to native LDL raised the abundance of ICER. Induction of this repressor by the modified LDL compromised the expression of important beta cell genes, including insulin and anti-apoptotic islet brain 1, as well as of genes coding for key components of the secretory machinery. This led to hampering of insulin production and secretion, and of cell survival. Silencing of this transcription factor by RNA interference restored the expression of its target genes and alleviated beta cell dysfunction and death triggered by oxidised LDL. Induction of ICER was stimulated by oxidative stress, whereas antioxidant treatment with N-acetylcysteine or HDL prevented the rise of ICER elicited by oxidised LDL and restored beta cell functions.

Conclusions/interpretation

Induction of ICER links oxidative stress to beta cell failure caused by oxidised LDL and can be effectively abrogated by antioxidant treatment.

Nur mit Berechtigung zugänglich

Donath MY, Ehses JA, Maedler K et al (2005) Mechanisms of β-cell death in type 2 diabetes. Diabetes 54(Suppl 2):S108–S113PubMedCrossRef

Brunham LR, Kruit JK, Verchere CB, Hayden MR (2008) Cholesterol in islet dysfunction and type 2 diabetes. J Clin Invest 118:403–408PubMedCrossRef

Hao M, Head WS, Gunawardana SC, Hasty AH, Piston DW (2007) Direct effect of cholesterol on insulin secretion: a novel mechanism for pancreatic beta-cell dysfunction. Diabetes 56:2328–2338PubMedCrossRef

Carpentier A, Mittelman SD, Bergman RN, Giacca A, Lewis GF (2000) Prolonged elevation of plasma free fatty acids impairs pancreatic beta-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes. Diabetes 49:399–408PubMedCrossRef

Poitout V, Robertson RP (2002) Minireview: secondary beta-cell failure in type 2 diabetes—a convergence of glucotoxicity and lipotoxicity. Endocrinology 143:339–342PubMedCrossRef

Okajima F, Kurihara M, Ono C, Nakajima Y et al (2005) Oxidized but not acetylated low-density lipoprotein reduces preproinsulin mRNA expression and secretion of insulin from HIT-T15 cells. Biochim Biophys Acta 1687:173–180PubMed

Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL (1989) Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320:915–924PubMedCrossRef

Ruderman NB, Haudenschild C (1984) Diabetes as an atherogenic factor. Prog Cardiovasc Dis 26:373–412PubMedCrossRef

Taskinen MR (2003) Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46:733–749PubMedCrossRef

10.

Nakhjavani M, Khalilzadeh O, Khajeali L et al (2010) Serum oxidized-LDL is associated with diabetes duration independent of maintaining optimized levels of LDL-cholesterol. Lipids 45:321–327PubMedCrossRef

11.

Cullen P, von Eckardstein A, Souris S, Schulte H, Assmann G (1999) Dyslipidaemia and cardiovascular risk in diabetes. Diabetes Obes Metab 1:189–198PubMedCrossRef

12.

Rohrer L, Hersberger M, von Eckardstein A (2004) High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease. Curr Opin Lipidol 15:269–278PubMedCrossRef

13.

Abderrahmani A, Niederhauser G, Favre D et al (2007) Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells. Diabetologia 50:1304–1314PubMedCrossRef

14.

Brewer HB Jr (2004) High-density lipoproteins: a new potential therapeutic target for the prevention of cardiovascular disease. Arterioscler Thromb Vasc Biol 24:387–391PubMedCrossRef

15.

Drew BG, Duffy SJ, Formosa MF et al (2009) High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 119:2103–2111PubMedCrossRef

16.

Rutti S, Ehses JA, Sibler RA et al (2009) Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells. Endocrinology 150:4521–4530PubMedCrossRef

17.

Maziere C, Morliere P, Santus R et al (2004) Inhibition of insulin signaling by oxidized low density lipoprotein. Protective effect of the antioxidant Vitamin E. Atherosclerosis 175:23–30PubMedCrossRef

18.

Stocker R, Keaney JF Jr (2004) Role of oxidative modifications in atherosclerosis. Physiol Rev 84:1381–1478PubMedCrossRef

19.

Tardif JC, McMurray JJ, Klug E et al (2008) Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet 371:1761–1768PubMedCrossRef

20.

Kaneto H, Matsuoka TA, Nakatani Y, Kawamori D, Matsuhisa M, Yamasaki Y (2005) Oxidative stress and the JNK pathway in diabetes. Curr Diabetes Rev 1:65–72PubMedCrossRef

21.

Kaneto H, Matsuoka TA, Katakami N et al (2007) Oxidative stress and the JNK pathway are involved in the development of type 1 and type 2 diabetes. Curr Mol Med 7:674–686PubMedCrossRef

22.

Beeler N, Riederer BM, Waeber G, Abderrahmani A (2009) Role of the JNK-interacting protein 1/islet brain 1 in cell degeneration in Alzheimer disease and diabetes. Brain Res Bull 80:274–281PubMedCrossRef

23.

Ferdaoussi M, Abdelli S, Yang JY et al (2008) Exendin-4 protects beta-cells from interleukin-1 beta-induced apoptosis by interfering with the c-Jun NH2-terminal kinase pathway. Diabetes 57:1205–1215PubMedCrossRef

24.

Molina CA, Foulkes NS, Lalli E, Sassone-Corsi P (1993) Inducibility and negative autoregulation of CREM: an alternative promoter directs the expression of ICER, an early response repressor. Cell 75:875–886PubMedCrossRef

25.

Abderrahmani A, Cheviet S, Ferdaoussi M, Coppola T, Waeber G, Regazzi R (2006) ICER induced by hyperglycemia represses the expression of genes essential for insulin exocytosis. EMBO J 25:977–986PubMedCrossRef

26.

Zhou YP, Marlen K, Palma JF et al (2003) Overexpression of repressive cAMP response element modulators in high glucose and fatty acid-treated rat islets. A common mechanism for glucose toxicity and lipotoxicity? J Biol Chem 278:51316–51323PubMedCrossRef

27.

Inada A, Hamamoto Y, Tsuura Y et al (2004) Overexpression of inducible cyclic AMP early repressor inhibits transactivation of genes and cell proliferation in pancreatic beta cells. Mol Cell Biol 24:2831–2841PubMedCrossRef

28.

Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D (1984) Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA 81:3883–3887PubMedCrossRef

29.

Cnop M, Hannaert JC, Grupping AY, Pipeleers DG (2002) Low density lipoprotein can cause death of islet beta-cells by its cellular uptake and oxidative modification. Endocrinology 143:3449–3453PubMedCrossRef

30.

Scheidegger KJ, Cenni B, Picard D, Delafontaine P (2000) Estradiol decreases IGF-1 and IGF-1 receptor expression in rat aortic smooth muscle cells. Mechanisms for its atheroprotective effects. J Biol Chem 275:38921–38928PubMedCrossRef

31.

Laoide BM, Foulkes NS, Schlotter F, Sassone-Corsi P (1993) The functional versatility of CREM is determined by its modular structure. EMBO J 12:1179–1191PubMed

32.

Thiel G, Lietz M, Hohl M (2004) How mammalian transcriptional repressors work. Eur J Biochem 271:2855–2862PubMedCrossRef

33.

Iezzi M, Escher G, Meda P et al (1999) Subcellular distribution and function of Rab3A, B, C, and D isoforms in insulin-secreting cells. Mol Endocrinol 13:202–212PubMedCrossRef

34.

Abderrahmani A, Niederhauser G, Plaisance V et al (2004) Complexin I regulates glucose-induced secretion in pancreatic β-cells. J Cell Sci 117:2239–2247PubMedCrossRef

35.

Wolff SP, Dean RT (1987) Glucose autoxidation and protein modification. The potential role of ‘autoxidative glycosylation’ in diabetes. Biochem J 245:243–250PubMed

36.

Berliner JA, Territo MC, Sevanian A et al (1990) Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest 85:1260–1266PubMedCrossRef

37.

Henriksen T, Mahoney EM, Steinberg D (1981) Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. Proc Natl Acad Sci USA 78:6499–6503PubMedCrossRef

38.

Kajimoto Y, Kaneto H (2004) Role of oxidative stress in pancreatic beta-cell dysfunction. Ann NY Acad Sci 1011:168–176PubMedCrossRef

39.

Rabinovitch A, Suarez-Pinzon WL, Strynadka K, Lakey JR, Rajotte RV (1996) Human pancreatic islet beta-cell destruction by cytokines involves oxygen free radicals and aldehyde production. J Clin Endocrinol Metab 81:3197–3202PubMedCrossRef

40.

Robbesyn F, Garcia V, Auge N et al (2003) HDL counterbalance the proinflammatory effect of oxidized LDL by inhibiting intracellular reactive oxygen species rise, proteasome activation, and subsequent NF-kappaB activation in smooth muscle cells. FASEB J 17:743–745PubMed

41.

Abderrahmani A, Plaisance V, Lovis P, Regazzi R (2006) Mechanisms controlling the expression of the components of the exocytotic apparatus under physiological and pathological conditions. Biochem Soc Trans 34:696–700PubMedCrossRef

42.

Inada A, Someya Y, Yamada Y et al (1999) The cyclic AMP response element modulator family regulates the insulin gene transcription by interacting with transcription factor IID. J Biol Chem 274:21095–21103PubMedCrossRef

43.

Nakhjavani M, Morteza A, Meysamie A et al (2010) Serum heat shock protein 70 and oxidized LDL in patients with type 2 diabetes: does sex matter? Cell Stress Chaperones 2:195–201

44.

Robertson RP (2004) Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J Biol Chem 279:42351–42354PubMedCrossRef

45.

Nakhjavani M, Asgharani F, Khalilzadeh O et al (2010) Oxidized low-density lipoprotein is negatively correlated with lecithin-cholesterol acyltransferase activity in type 2 diabetes mellitus. Am J Med Sci 2:92–95

46.

Kaneto H, Kajimoto Y, Miyagawa J et al (1999) Beneficial effects of antioxidants in diabetes: possible protection of pancreatic beta-cells against glucose toxicity. Diabetes 48:2398–2406PubMedCrossRef

47.

Paolisso G, D’Amore A, Galzerano D et al (1993) Daily vitamin E supplements improve metabolic control but not insulin secretion in elderly type II diabetic patients. Diabetes Care 16:1433–1437PubMedCrossRef

48.

Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A (2003) Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 26:3264–3272PubMedCrossRef

49.

Gorogawa S, Kajimoto Y, Umayahara Y et al (2002) Probucol preserves pancreatic beta-cell function through reduction of oxidative stress in type 2 diabetes. Diabetes Res Clin Pract 57:1–10PubMedCrossRef

50.

Millea PJ (2009) N-acetylcysteine: multiple clinical applications. Am Fam Physician 80:265–269PubMed

Titel: Role for inducible cAMP early repressor in promoting pancreatic beta cell dysfunction evoked by oxidative stress in human and rat islets
verfasst von: D. Favre
G. Niederhauser
D. Fahmi
V. Plaisance
S. Brajkovic
N. Beeler
F. Allagnat
J. A. Haefliger
R. Regazzi
G. Waeber
A. Abderrahmani
Publikationsdatum: 01.09.2011
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 9/2011
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-011-2165-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2011

Type 2 diabetes: unravelling the interaction between genetic predisposition and lifestyle

Dynamic evaluation of renal resistive index in normoalbuminuric patients with newly diagnosed hypertension or type 2 diabetes

Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe alpha cell hypertrophy in diet-induced obese mice

Incidence and progression of diabetic retinopathy in Japanese adults with type 2 diabetes: 8 year follow-up study of the Japan Diabetes Complications Study (JDCS)

Leptin administered in physiological or pharmacological doses does not regulate circulating angiogenesis factors in humans